Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RGNX | US
-0.20
-2.02%
Healthcare
Biotechnology
30/06/2024
04/10/2024
9.72
9.45
9.81
9.40
REGENXBIO Inc. a clinical-stage biotechnology company provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration diabetic retinopathy and other chronic retinal diseases; and RGX-202 which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111 which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville Maryland.
View LessValue Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
33.1%1 month
52.1%3 months
62.8%6 months
55.3%-
-
1.53
0.46
0.28
-3.37
3.69
0.26
-226.02M
480.39M
480.39M
-
-251.34
-
11.60
-63.94
17.35
16.42
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.07
Range1M
4.08
Range3M
5.96
Rel. volume
0.77
Price X volume
4.34M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 9.97 | 518.14M | -2.92% | n/a | 2.32% |
Third Harmonic Bio Inc. | THRD | Biotechnology | 12.52 | 514.54M | -0.71% | n/a | 1.40% |
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
PureTech Health plc | PRTC | Biotechnology | 20.33 | 486.74M | 5.39% | n/a | 29.73% |
Anavex Life Sciences Corp | AVXL | Biotechnology | 5.595 | 474.43M | -1.06% | n/a | 0.00% |
OABI | OABI | Biotechnology | 3.99 | 471.47M | -1.97% | n/a | 8.27% |
Valneva SE | VALN | Biotechnology | 5.8116 | 471.18M | 1.78% | n/a | 126.08% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.37 | 0.76 | Cheaper |
Ent. to Revenue | 3.69 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.53 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 62.76 | 74.67 | Par |
Debt to Equity | 0.46 | -1.82 | Expensive |
Debt to Assets | 0.28 | 0.26 | Par |
Market Cap | 480.39M | 3.73B | Emerging |